Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple

J A Cabrera-Gómez1, N Echazábal-Santana, P Porrero-Martín

  • 1Grupo Cubano para la Investigación y el Tratamiento de la Esclerosis Múltiple, Cienfuegos, Cuba. cabrera@jagua.cfg.sld.cu

Revista De Neurologia
|August 26, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes for people with TB by disease severity at presentation.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Reply to 'Estimating TB survival - mind the immortal-time gap'.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Treatment of landfill leachate by combined use of ultrasound and photocatalytic process using fly ash as catalyst.

Journal of environmental management·2023
Same author

Survival of people with untreated TB: effects of time, geography and setting.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

A novel Notch 3 mutation (pathogenic variant c.1565G>C) in CADASIL.

Neurologia·2022
Same author

A facile synthesis of CuBi<sub>2</sub>O<sub>4</sub> hierarchical dumbbell-shaped nanorod cluster: a promising photocatalyst for the degradation of caffeic acid.

Environmental science and pollution research international·2022

Interferon-alpha (IFN-alpha) treatment significantly improved cognitive dysfunction in relapsing remitting multiple sclerosis (RR-MS) patients. Higher doses of IFN-alpha demonstrated greater benefits in cognitive function compared to placebo.

Area of Science:

  • Neuroscience
  • Immunology
  • Clinical Trials

Background:

  • Relapsing remitting multiple sclerosis (RR-MS) is often associated with cognitive dysfunction.
  • Preliminary studies suggest alpha-interferon (IFN-alpha) may be beneficial for RR-MS.
  • Cuban reports indicated that 70% of MS patients experience cognitive impairment.

Purpose of the Study:

  • To evaluate the efficacy of recombinant IFN-alpha2b in treating cognitive dysfunction in RR-MS patients.
  • To compare the effects of low-dose and high-dose IFN-alpha2b against a placebo.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 57 RR-MS patients.
  • Patients received intramuscular IFN-alpha2b (low or high dose) or placebo twice weekly for two years.

Related Experiment Videos

  • Cognitive function was assessed using Luria, WAIS, Benton, and PASAT-3 tests.

    • Main Results:

    • Both low-dose and high-dose IFN-alpha2b groups showed significant improvements in Luria, Benton, WAIS, and PASAT-3 test scores compared to placebo.
    • Cognitive function in the placebo group showed no improvement or worsened across tests.
    • No significant differences were observed between groups regarding age, gender, ethnicity, disease duration, or relapse rate.

    Conclusions:

    • IFN-alpha2b treatment effectively improved cognitive dysfunction in RR-MS patients.
    • A higher dose of IFN-alpha2b appeared to yield more significant cognitive benefits.
    • IFN-alpha represents a potential therapeutic option for cognitive impairment in RR-MS.